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Abstract
Aim: To test the psychometric properties and clinical usability of a new Pressure
Ulcer Risk Assessment Instrument including inter-rater and test–retest reliability,
convergent validity and data completeness.
Background: Methodological and practical limitations associated with traditional
Pressure Ulcer Risk Assessment Instruments, prompted a programme to work to
develop a new instrument, as part of the National Institute for Health Research
funded, Pressure UlceR Programme Of reSEarch (RP-PG-0407-10056).
Design: Observational field test.
Method: For this clinical evaluation 230 patients were purposefully sampled across
four broad levels of pressure ulcer risk with representation from four secondary
care and four community NHS Trusts in England. Blinded and simultaneous paired
(ward/community nurse and expert nurse) PURPOSE-T assessments were under-
taken. Follow-up retest was undertaken by the expert nurse. Field notes of PUR-
POSE-T use were collected. Data were collected October 2012–January 2013.
Results: The clinical evaluation demonstrated “very good” (kappa) inter-rater and
test–retest agreement for PURPOSE-T assessment decision overall. The percentage
agreement for “problem/no problem” was over 75% for the main risk factors. Con-
vergent validity demonstrated moderate to high associations with other measures of
similar constructs.
Conclusion: The PURPOSE-T evaluation facilitated the initial validation and clinical
usability of the instrument and demonstrated that PURPOSE-T is suitable of use in
clinical practice. Further study is needed to evaluate the impact of using the instru-
ment on care processes and outcomes.
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1 | INTRODUCTION
Pressure Ulcers (PUs) are “localized injury to the skin and/or under-
lying tissue usually over a bony prominence, as a result of pressure,
or pressure in combination with shear” (NPUAP/EPUAP/PPPIA,
2014). Skin sites susceptible to PUs are those exposed to pressure
(e.g. buttocks and heels) in patients with very limited mobility where
offloading is difficult. PUs are categorized numerically according to
the tissue layers involved; category 1 indicates non-blanchable ery-
thema and category 4 indicates full thickness tissue Loss (NPUAP/
EPUAP/PPPIA, 2014).
PUs remain a considerable patient safety issue worldwide with
prevalence in acute care settings being 11.9–15.8% and incidence
being 2.8–9.0% (Briggs et al., 2013; Pieper, 2012; Smith, Nixon,
Brown, Wilson, & Coleman, 2016). PUs cause undue burden on
patients quality of life (Gorecki et al., 2009; Gorecki, Nixon, Madill,
Firth, & Brown, 2012) and have a significant financial impact
to healthcare organizations (Bennett, Dealey, & Posnett, 2004;
Berlowitz et al., 2011; Dealey, Posnett, & Walker, 2012;
Schuurman et al., 2009; Severens, Habraken, Duivenvoorden, &
Frederiks, 2002). National and international guidelines agree that
structured risk assessment is the cornerstone to PU prevention
(Beeckman et al., 2013; NICE, 2014, NPUAP/EPUAP/PPPIA,
2014).
2 | BACKGROUND
In clinical practice structured risk assessment is underpinned by rou-
tine use of PU Risk Assessment Instruments (PU-RAIs). These assist
nurses to identify those at risk with the aim of appropriately target-
ing preventative interventions. Since the 1960s over 40 PU-RAIs
have been developed (Nixon & McGough, 2001), though their
methodological development and conceptual and practical founda-
tion are often limited. This was demonstrated by analysis of 14 PU-
RAIs included in a recent NICE systematic review (NICE, 2014)
which identified the following (Coleman, 2014):
• Lack of conceptual framework—only two PU-RAIs (Braden &
Bergstrom, 1987; Suriadi, Sanada, Sugama, Thigpen, & Subuh,
2008) were underpinned by a conceptual framework.
• Inadequate development methods—only thee PU-RAIs were
developed from limited statistical modelling methods (Page, Bar-
ker, & Kamar, 2011; Perneger et al., 2002; Suriadi et al., 2008)
with the remainder developed on the basis of clinical opinion
and/or out-dated literature reviews or adaptations of original
instruments.
• Limited evidence of target population involvement during devel-
opment (SAC, 2002)—involvement of both clinical nurses and
patient/carers is important as while nurses primarily use the
instruments, assessment should involve the patient/carer and
where possible lead to shared decision-making about care (Cole-
man, 2014).
• Inconsistent risk factor inclusion—for example only five PU-RAIs
include skin status (Andersen, Jensen, Kvorning, & Bach, 1982;
Cubbin & Jackson, 1991; Kwong et al., 2005; Pritchard, 1986;
Waterlow, 1985) yet a systematic review identified this as a key
predictor of PU development (Coleman et al., 2013).
These issues undermine the content validity of PU-RAIs which is
a fundamental property and raises concern about their ability to
identify risk adequately (Coleman, 2014; Gould, Goldstone, Gammon,
Kelly, & Maidwell, 2002; Kottner & Balzer, 2010; Nixon & McGough,
Why is this research or review needed?
• There are methodological and practical limitations associ-
ated with the development and use of traditional Pres-
sure Ulcer Risk Assessment Instruments.
• Recent work has been undertaken to develop a new Risk
Assessment Instrument, incorporating: (1) a systematic
review; (2) a consensus study; (3) conceptual framework
development; (4) Pre-test study.
• This phase 5 clinical evaluation paper, reports a subse-
quent fundamental step in the development of the Pres-
sure Ulcer Risk Primary Or Secondary Evaluation Tool
(PURPOSE-T) to confirm its suitability for use in clinical
practice.
What are the key findings?
• The clinical evaluation of PURPOSE-T demonstrated the
reliability, convergent validity and clinical usability of the
instrument when used by expert and ward/community
nurses in secondary care and community settings.
• The findings emphasize the importance of including skin
status in the assessment process facilitate both primary
and secondary prevention.
• The clinical evaluation aided refinement of the instru-
ment and confirmed its suitability for use in clinical prac-
tice.
How should the findings be used to influence
policy/practice/research/education?
• The clinical evaluation, was an important phase in the
instruments development and the methods used should
be considered by others developing health-related instru-
ments.
• PURPOSE-T translates pressure ulcer risk factor evidence
and expert opinion into a usable instrument that can
facilitate the identification and management of pressure
ulcer risk in practice.
• PURPOSE-T should be considered for clinical use in adult
hospital and community populations.
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2001). There are also practical limitations associated with their use
(Coleman, 2014; Coleman, Nelson, et al., 2014; Nixon et al., 2015):
• PU-RAIs are undertaken on all patients, including full assessment
of those who are obviously not at risk, which diverts time away
from other important care activities.
• Failure to distinguish between those with and without an existing
PU which is important as those with a PU require intensified sec-
ondary prevention/treatment.
• Use of condensed numerical scores as a basis for care interven-
tions which do not facilitate consideration of individual risk pro-
files in care-planning.
To address these conceptual, methodological and practical limita-
tions we developed the Pressure Ulcer Risk Primary Or Secondary
Evaluation Tool, PURPOSE-T as part of a NIHR funded PU Pro-
gramme Of Research (PURPOSE: RP-PG-0407-10056). PURPOSE-T
development drew on principles of the MRC complex intervention
framework (MRC, 2000, 2008) and incorporated adapted “gold stan-
dard” instrument development methods (FDA DHHS, 2009, Mokkink
et al., 2012, SAC, 2002; Steyerberg, 2010), in a structured five phase
approach:
1. Systematic review (Coleman et al., 2013)
2. Consensus study (Coleman, Nelson, et al., 2014)
3. Conceptual framework development (Coleman, Nixon, et al.,
2014)
4. Design and pre-testing (Coleman et al., 2016)
5. Clinical evaluation (Nixon et al., 2015)
The first four phases of this work were concerned with providing
evidence of content validity which was indicated along with usability
and acceptability in the phase iv) design and pre-test (Coleman et al.,
2016). This led to the development of the preliminary PURPOSE-T
for clinical evaluation.
2.1 | Aims
The aim of the study was to test the psychometric properties and
clinical usability of PURPOSE-T including inter-rater and test–retest
reliability, convergent validity and data completeness.
2.2 | Design
PURPOSE-T clinical evaluation comprised a field test of hospital and
community patients using observational descriptive methods (Nixon
et al., 2015). The psychometric properties assessed included reliabil-
ity defined as “the extent to which scores for patients who have not
changed are the same for repeated measurement under several con-
ditions” (Mokkink et al., 2012). In this study, we considered this over
time (test–retest) when assessed by the same nurse and on the same
occasion by different nurses (inter-rater). Convergent validity was
assessed for expected correlations between the items and overall
assessment decision of PURPOSE-T and other PU-RAIs to demon-
strate construct validity, that is “evidence that relationships among
items, domains and concepts conform to a priori hypotheses con-
cerning logical relationships that should exist with measures of
related concepts or scores produced in similar or diverse patient
groups” (FDA DHHS, 2009). In addition, the extent to which scale
items were completed and used to allocate risk and the experience
of using PURPOSE-T in clinical practice were captured.
3 | PARTICIPANTS
3.1 | Nurses
Expert nurses were trained how to use PURPOSE-T via presentation,
the use of vignette case studies, user manual provision and
researcher (SC) support. The expert nurses used the same material
to cascade PURPOSE-T training to participating ward/community
nurses (Nixon et al., 2015).
3.2 | Patients
Patients were purposively sampled ensuring a similar number of hos-
pital and community patients and representation of patients across
four broad risk levels (Nixon et al., 2015). These comprised those
without mobility restriction (i.e. low risk), those with some mobility/
activity limitations (i.e. at risk), those who were bedfast/chairfast (i.e.
high risk) and those with an existing PU category 1 or above.
Eligible patients included those who were: ≥18 years, an inpa-
tient in an acute setting or nursing patient in a community setting,
able to provide written informed consent/verbal witnessed consent/
consultee agreement and expected to be available for PURPOSE-T
retest. Patients were excluded if they were from obstetric, paedi-
atric, day case surgery or psychiatric settings, deemed by the attend-
ing healthcare professional to be too unwell to be approached or
complete the study assessment schedule.
3.3 | Sample size
The sample size was calculated using PASS software is based on a
measure of reliability, specifically the kappa coefficient, j, defined as
the proportion of agreement after chance agreement is removed
from consideration (Cohen, 1960). Assuming a null hypothesis of
j = 0.6,5% significance level and 15% withdrawal/non-compliance in
paired assessments and 25% of patients are assessed as “not at risk”
and 75% of patients are assessed as “at risk,” 230 patients were
required to be recruited to the study to detect a statistically signifi-
cant value of j ≥ 0.8 (alternative hypothesis) with at least 90%
power. For the evaluation of screening instruments, no examples of
formal sample size estimation methods were identified in the litera-
ture (Nixon et al., 2015). Therefore, literature relating to the psycho-
metric evaluation of rating scales was considered. The “rule of
thumb” recommendation of 5–10 patients for every item in a ques-
tionnaire was used to estimate the sample size of 115–230 patients
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(Blazeby, Sprangers, Cull, Groenvold, & Bottomley, 2002; Nunnally &
Bernstein, 1994). Therefore, the proposed sample size of 230 to
assess inter-rater reliability of the instrument, with >95% expert
nurse data compliance (based on previous research experience), was
expected to provide a sufficient number of patients to assess the
validity of the risk assessment instrument.
3.4 | Data collection
Hospital inpatients and community nursing patients were invited to
participate. Ward/community-based nurses identified suitable
patients from their area of practice. Attending clinical staff or a
member of the tissue viability team provided the patient with a ver-
bal explanation of the study and an information leaflet before they
were invited to provide informed, written consent. Assessment of
eligibility and informed consent/consultee agreement was under-
taken by a member of the tissue viability team. Participants were
registered centrally using the CTRU automated 24-hour telephone
registration system (Nixon et al., 2015).
Participant baseline assessment was undertaken by an expert
nurse (tissue viability nurse consultant/specialist/clinical research
nurse) and incorporated the collection of demographic data including
type of NHS facility, type of admission/referral (e.g. elective/acute),
ward specialty (hospital patients), date of birth, gender, ethnicity and
clinical assessment comprising subscales of established PU-RAIs, the
Braden scale (Bergstrom, Braden, Laguzza, & Holman, 1987) and
Waterlow score (Waterlow, 1988). Braden and Waterlow were
selected as they have undergone the most scrutiny in the literature,
reflecting their widespread use in practice (Gould et al., 2002; NICE,
2014; Pancorbo-Hidalgo et al., 2006). Waterlow incorporates mobil-
ity, moisture, perfusion, nutrition, gender, age, sensory perception,
orthopaedic surgery/below waist fracture, skin condition and medi-
cation, whereas the Braden incorporates mobility, activity, friction
and shear, moisture, sensory perception and nutrition. Both are ordi-
nal scoring systems where scores for each risk factor are added
together to give the patients overall score. This overall score is then
compared with a standard reference value to allocate a risk category
(e.g. high risk, moderate risk, at risk).
In addition, a paired PURPOSE-T assessment was undertaken by
the expert nurse and a ward/community nurse, incorporating
detailed skin assessment and when applicable, PU classification (1–4
and unstageable categories) (NPUAP/EPUAP/PPPIA, 2014). These
were conducted simultaneously by both assessors, but recorded sep-
arately with blinding maintained (Nixon et al., 2015).
The expert nurse also undertook a second visit and completed
PURPOSE-T (blind to their initial assessment) and recorded signifi-
cant clinical changes to the patient’s condition since the baseline
assessment (Nixon et al., 2015).The length of the test–retest interval
was planned to be short enough to ensure that clinical change in PU
risk was unlikely to occur but sufficiently long to be confident that
the expert nurse did not recall responses from the first assessment.
Nurses were asked to plan their retest visit 1–3 days and 1-7 days
after baseline for hospital and community patients, respectively,
taking into account anticipated recovery/deterioration/stability of
each patient’s condition and, for hospital patients, length of stay.
Expert nurses also kept field notes of their experience of using PUR-
POSE-T and comments from ward/community nurses (Nixon et al.,
2015).
3.5 | The instrument
The preliminary PURPOSE-T incorporates instructions to support
nurse decision-making facilitated by the use of colour to weight risk
factor items. This was based on the overall strength of epidemiologi-
cal evidence and/or wider scientific evidence, its clinical resonance
and its role in the PU causal pathway (Coleman et al., 2013; Cole-
man, Nelson, et al., 2014; Coleman, Nixon, et al., 2014). In PUR-
POSE-T blue indicates “no problem;” yellow indicates a potential
impact on PU risk; orange indicates risk and; pink indicates the
patient has a PU or scar from a previous PU. This colour code is
integrated throughout the three-step assessment process:
• Step 1—screening assessment comprises 4 mobility items (one
blue, three yellow) and four skin status items (one blue, two yel-
low, one pink). This allows those who are clearly not at risk (with
only blue items) to be quickly screened out and those with
potential risk or actual PUs to proceed to the full assessment.
• Step 2—full assessment comprises items for analysis of indepen-
dent movement (five items which include parameters relating to
the extent and frequency of movement; one yellow, four orange);
sensory perception (two items; one blue, one orange), detailed
skin assessment (13 skin sites each with three items relating to;
normal skin (blue), vulnerable skin (orange) or PU (pink) and there
is an option to add further skin sites assessed as vulnerable or
with a PU in addition to the pre-specified list); previous PU his-
tory (three items; one blue, one yellow and a potential additional
pink, yellow or blue); perfusion (three items; one blue two
orange), nutrition (five items; one blue, four orange), moisture
(three items; one blue, two yellow) and diabetes (two items; one
blue, one yellow).
• Step 3—requires consideration of step 2 responses to inform 1
of 3 assessment decisions comprising “no PU not currently at
risk” for those with only yellow or blue items ticked; “no PU but
at risk” for those with any orange (but no pink items) ticked or if
yellow/blue boxes are ticked and the nurse assesses the patient
to be at risk based on their overall risk profile; and “PU category
1 or above or scarring from previous PU” for those with any pink
items ticked.
The final version of PURPOSE-T is available at http://medhealth.
leeds.ac.uk/accesspurposet.
3.6 | Ethical considerations
Patients at risk of PUs are often elderly, frail and considered vulnera-
ble. NHS ethical approval for the study was sought through the
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Health Research Authority and the Integrated Research Application
System and Research Ethics Committee.
3.7 | Data analysis
3.7.1 | Study risk definitions
For the purposes of describing the study population and to assess
the convergent validity of PURPOSE-T with other PU-RAIs, “at risk”
was defined as decision pathways “No PU but at risk” and “PU cate-
gory 1 or above or scarring from previous PU,” whereas “not at risk”
was defined as decision pathway “no PU not currently at risk”. The
cut-points used to identify patients at risk for the two other PU-RAIs
were ≤18 for Braden (Bergstrom, Braden, Kemp, Champagne, &
Ruby, 1998) and ≥10 for Waterlow (Waterlow, 1988).
3.7.2 | Analysis
For each assessment data completeness was summarized for each
element of PURPOSE-T including the percentage of missing item-
level data and risk categories allocated. We produced the simple
kappa statistic with 95% confidence interval (CI) and a weighted
kappa statistic which incorporates the distribution of disagreements.
We calculated weighted Kappa using (Cicchetti & Allison, 1971)
weights for comparisons of outcomes with more than two levels.
Prevalence-adjusted bias-adjusted kappa (PABAK) statistics were also
produced to take into account the prevalence of risk status and bias
between observers (Byrt, Bishop, & Carlin, 1993). The final kappa
statistic calculated to assess the inter-rater and test–retest reliability
for overall risk status was the maximum value of kappa (jmax) statis-
tic. Cross-tabulations of overall risk status by rater/retest were also
produced. We examined the extent of agreement for individual PUR-
POSE-T items using cross-tabulations by rater/retest. In addition, we
produced kappa (with 95% CI) and weighted kappa statistics to
assess inter-rater reliability of the PURPOSE-T decision pathway and
produced corresponding cross-tabulations by rater/retest. We used
published benchmarks to interpret estimates of the kappa coeffi-
cient; Poor j < 0.20, Fair 0.21 ≤ j ≤ 0.40, Moderate 0.41 ≤ j ≤
0.60, good 0.61 ≤ j ≤ 0.80, very good 0.81 ≤ j ≤ 1.00 (Bland, 2008;
Landis & Koch, 1977).
Cross-tabulations of overall risk status for PURPOSE-T, Braden
and Waterlow were produced to explore convergent validity.
Cross-tabulations of corresponding items between PURPOSE-T,
Braden and/or Waterlow were produced and correlation coeffi-
cients were calculated to assess convergent validity. The Spearman
rank correlation coefficient was used when each of the items
being compared had more than two levels and the phi correlation
coefficient was calculated when dichotomous variables were com-
pared. For exploratory purposes, the following hypotheses were
used as guides to the magnitude of correlations: high correlation
r > 0.7; moderate correlation 0.3 ≤ r ≤ 0.7; low correlation r < 0.3
(Burnand, Kernan, & Feinstein, 1990; Cohen, 1960). Moderate to
high correlations (r ≥ 0.3) were predicted for comparison of
PURPOSE T with relevant Braden and Waterlow items. SAS 9.2
was used for the analysis.
3.8 | Validity and reliability
To maintain blinding between assessors (expert and ward/commu-
nity nurses) and assessments (baseline and follow-up), special adhe-
sive data collection forms were used that were sealed on
completion, only being opened by CTRU for analysis (Nixon et al.,
2015).
To ensure the study population was representative of the clinical
population assessed in the course of usual care, approval was sought
and gained for witnessed consent (for patients who were capable of
giving consent but physically unable to complete the consent form)
and consultee agreement (for patients who lacked capacity).
4 | RESULTS
In total, 230 of 394 patients screened were registered to the study
between 3 October 2012–25 January 2013 (Figure 1), from four
acute hospital (108 (47.0%) patients) and four community NHS trusts
(122 (53.0%) patients) in England, with numbers of patients regis-
tered at each centre ranging from 14 to 54. The 230 patients
recruited were assessed in part or full using PURPOSE-T at baseline,
providing a total of 230 paired assessments undertaken by 11 expert
nurses and 73 ward/community nurses. Table 1 shows the charac-
teristics of participants, indicating a mainly Caucasian population
with good representation from each of the four broad levels of risk.
Of the 230 patients registered, 217 (94.3%) had retest assessments
completed by the expert nurse (Figure 1).
Based on the baseline PURPOSE-T assessment conducted by
expert nurses, there were 60 (26.1%) patients who presented with a
category 1 or above PU (Table 1). There were a total of 96 PUs
across the 60 patients including 21 (21.9%) category 1, 56 (58.3%)
category 2, 6 (6.3%) category 3, 6 (6.3%) category 4 and 7 (7.3%)
unstageable ulcers. PURPOSE-T identified 183(79.6%) patients as “at
risk,” Waterlow identified 193 (83.9%) patients as “at risk” and Bra-
den identified 85 (37.0%) patients as “at risk.” Of the 145 patients
identified as “not at risk” on Braden 25 (17.2%) had an existing PU
(Table 1).
4.1 | Data completeness and usability
Compliance with the completion guidelines for steps 1–3 were quan-
tified together with a review of the field notes from the expert
nurses (Table 2). At least 94.9% data completeness for each con-
struct was observed with the exception of previous PU details
(54.7% and 66.7%) and the decision pathway allocation by the ward/
community nurses for patients who should not have progressed to
step 2 (85.7%) (Table 2).
Appropriate completion of Step 1 (i.e. in line with the recom-
mended assessment flow) by the expert nurses was similar for
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baseline (83.5%:192/230) and follow-up (82.9%:180/217), respec-
tively, compared with 72.6% (167/230) of ward/community nurses
assessments (Table 2). Progression/non-progression to step 2 was
completed in line with the recommended assessment flow for 95.7%
(220/230) of patients assessed by an expert nurse at baseline and
98.6% (214/217) assessed at follow-up. For ward/community nurses
this was 94.3% (217/230) (Table 2). A step1/step 3 decision
pathway was allocated to all patients by the expert nurses at base-
line and follow-up and just one patient (0.4%) was not allocated a
decision pathway by the ward/community nurses (Table 2).
Patients were allocated (Tables 2 and 3) to the correct decision
pathway (i.e. in line with PURPOSE-T decision rules) by expert
nurses at baseline (98.3%:226/230) and follow-up (99.1%: 215/217)
and by ward/community nurses (95.2%:219/230). Expert and ward/
Screened
N = 394
Assessed for eligibility
N = 392/394 (99.5 %)
Eligible for study entry
N = 350/392 (89.3 %)
Eligible and consented
N = 234/350 (66.9 %)
Consented and registered
N = 230/234 (98.3 %)
Follow-up assessment
N = 217/230 (94.3 %)
Not eligible for study entry
N = 42/392 (10.7 %)
1 (2.4 %)
1 (50.0 %) Reason not provided
1 (50.0 %)
58 (50.0 %)
16 (13.8 %)
18 (15.5 %)
6 (5.2 %)
18 (15.5 %)
1 (7.7 %)
1 (7.7 %)
8 (61.5 %) Patient discharged
3 (23.1 %) Other reason
Other reason
Reason not provided
Unable to give
consent/consultee
agreement
12 (28.6 %)
17 (40.5 %) Patient is not expected to
be able to comply with
follow-up schedule
Patient is too unwell to be
approached
12 (28.5 %)
1 (25.0 %) Feeling unwell on the day
of paired assessment
1 (25.0 %) Following
Waterlow/Braden
assessments, patient
refused any further
assessments
1 (25.0 %)
1 (25.0 %)
Not registered
N = 4/234 (1.7 %)
Not able to assess on day
of consent. Patient
changed mind at next
opportunity
Unable to do paired
assessment due to
patients busy schedule.
Ethically inappropriate to
approach the patient
Reason not provided
Patient finds follow-up
schedule inconvenient
Patient feels poorly or
unwell
Patient does not want to
be involved in research
Patient refused without
any reason
Not consented
N = 116/350 (33.1 %)
Ethically inappropriate to
approach the patient
Not assessed for eligibility
N = 2/394 (0.5 %)
No follow-up assessment
N = 13/230 (5.7 %)
F IGURE 1 Flow of participants
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community nurses allocated most of patients to the “not at risk”
decision pathway when they completed only yellow and blue boxes
with 95.6% (43/45), 95.9% (47/49) and 97.7% (42/43) for expert
nurses at baseline, ward/community nurses and expert nurses at fol-
low-up respectively (Table 3).
4.2 | Inter-rater reliability
At baseline, there were 230 paired assessments by the expert nurse
and the ward/community nurse for evaluating inter-rater reliability.
The patient population included patients for whom the assessment
was completed by both raters regardless of compliance with the rec-
ommended assessment flow (Table 2).
There was agreement in the three-way decision pathway
between expert and ward/community nurses for 81.7% (187/229)
of paired assessments (Table 4). Under the assumption that the
expert nurse and ward/community nurse would complete PUR-
POSE-T in a similar manner, the corresponding simple kappa
statistic of 0.71 (95% CI 0.63 to 79) and weighted kappa statistic
of 0.76 (95% CI 0.69 to 0.83) indicate good inter-rater reliability.
When classified dichotomously as “at risk”/”not at risk” there was
agreement between the expert nurse and ward/community nurse
for 93.4% (214/229) paired assessments (Table 4). The corre-
sponding simple kappa statistic of 0.81 (95% CI 0.71 to 0.90),
PABAK of 0.87 and jmax of 0.94 indicate very good inter-rater
reliability.
TABLE 1 Baseline characteristics
Variable
PU at baselinea
(N = 60)
No PU at baselinea
(N = 169)
Missing PU
statusa (N = 1b) Totalc
Age (years)
Mean (SD) 73.8 (15.9) 72.1 (18.3) – 72.6 (17.6)
Median (range) 76 (29, 98) 78 (19,102) 78 (N/A) 77 (19, 102)
Sex, N (%)
Male 27 (27.3%) 72 (72.7%) 0 (0.0%) 99 (43.0%)
Female 33 (25.2%) 97 (74.0%) 1 (0.8%) 131 (57.0%)
Ethnicity N (%)
Caucasian 58 (25.9%) 165 (73.7%) 1 (0.4%) 224 (97.4%)
Other 2 (33.3%) 4 (66.7%) 0 (0.0%) 6 (2.6%)
Setting, N (%)
Community 37 (30.3%) 84 (68.9%) 1 (0.1%) 122 (53.0%)
Secondary care hospital 23 (21.3%) 85 (78.7%) 0 (0.0%) 108 (47.0%)
Mobility status, PURPOSE-T step 1, N (%)
Walks independently with or without walking aids 10 (12.7%) 69 (87.3%) 0 (0.0%) 79 (34.3%)
Needs help of another person to walk 6 (22.2%) 21 (77.8%) 0 (0.0%) 27 (11.7%)
Spends all/majority of time in bed/chair 16 (28.1%) 40 (70.2%) 1 (1.8%) 57 (24.8%)
Remains in same position for long periods 28 (42.4%) 38 (57.6%) 0 (0.0%) 66 (28.7%)
Not completed 0 (0.0%) 1 (100%) 0 (0.0%) 1 (0.4%)
Braden score, N (%)
At risk (≤18) 35 (41.2%) 50 (58.8%) 0 (0.0%) 85 (37.0%)
Not at risk (>18) 25 (17.2%) 119 (82.1%) 1 (0.7%) 145 (63.0%)
Waterlow total score
At risk (≥10) 60 (31.1%) 132 (68.4%) 1 (0.5%) 193 (83.9%)
Not at risk (<10) 0 (0.0%) 37 (100%) 0 (0.0%) 37 (16.1%)
PURPOSE-T risk categorization
Secondary prevention/treatment pathway 60 (83.3%) 12 (16.7%) 0 (0.0%) 72 (31.3%)
Primary prevention pathway 0 (0.0%) 111 (100%) 0 (0.0%) 111 (48.3%)
Not currently at risk pathway 0 (0.0%) 46 (97.9%) 1 (2.1%) 47 (20.4%)
aPercentages in the PU status columns correspond to the proportion of patients within that characteristic who do (or do not) have a PU at baseline (e.g.
27.3% (27 out of 99) of the male population were observed to have a PU at baseline).
bThere was one community patient for whom their PU status at baseline could not be determined as there were no skin assessments recorded by the
tissue viability team member.
cPercentages in the total column correspond to the proportion of patients from the overall population with that characteristic (e.g. 43.0% of overall pop-
ulation were male; 57.0% female).
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Table 5 shows the level of agreement between expert nurses
and ward/community nurses for specific risk factor items. In terms
of complete agreement, the lowest level was 59.2% (113/191) for
the analysis of independent movement and the highest was 94.2%
(180/191) for diabetic status. We also looked at the levels agree-
ment in terms of the presence of a problem or not and the levels of
agreement; ranged from 72.8% (139/191) for perfusion status to
94.2% for diabetic status.
4.3 | Test–retest reliability
There were up to 217 paired assessments by the expert nurse at base-
line and at follow-up for evaluating test–retest reliability, however, four
were excluded due to a change in the patients’ clinical condition provid-
ing an analysis population of 213. The median number of days between
the baseline and the retest expert nurse assessment was three (range
1–7). As with the inter-rater reliability, the patient population included
patients for whom the assessment was completed at both time points
regardless of compliance with the recommended assessment flow.
There was agreement in the three-way decision pathway
between the baseline and follow-up assessments for 92.0% (196/
213) of paired assessments (Table 4). The corresponding simple
kappa statistic of 0.87 (95% CI 0.81-93) and weighted kappa statistic
of 0.89 (95% CI 0.84-0.94) indicate good test–retest reliability.
When classified dichotomously as “at risk”/”not at risk” there was
agreement between the baseline and follow-up assessment for 204
(95.8%) paired assessments (Table 4). The corresponding simple
kappa statistic of 0.87(95% CI 0.78-0.95), PABAK of 0.92 and
jmax of 0.99 indicate very good test–retest reliability.
Table 5 shows the level of agreement between expert nurse’s
baseline and follow-up assessments for specific risk factor items. In
terms of complete agreement, the lowest level was 64.4% (114/177)
for the analysis of independent movement and the highest was
96.0% (170/177) for low BMI. We also looked at the levels of agree-
ment in terms of the presence of a problem or not and levels of
agreement ranged from 87.0% (154/177) for perfusion status to
96.0% (170/177) for low BMI.
4.4 | Convergent validity
The overall risk status on PURPOSE-T was compared with Waterlow
for all 230 patients PU free at baseline. A moderate association was
observed between PURPOSE-T and Waterlow with a phi correlation
coefficient of 0.63 (Table 6). A moderate association was also
observed between PURPOSE-T and Braden for 169 PU-free patients,
as assessed by the expert nurse at baseline, with a phi correlation
coefficient of 0.40. Individual constructs on PURPOSE-T were com-
pared with relevant constructs on Braden and Waterlow with moder-
ate to high correlations observed in each case (Tables 7 & 8).
4.5 | Summary of expert nurse field notes
The field notes described positive and problem aspects of using
PURPOSE-T in practice (Table 9). More general issues associated
with all PU-RAIs were reported (Nixon et al., 2015):
• Lack of knowledge of PU classification
• Difficulty assessing:
TABLE 3 PURPOSE T decision pathway by colour of boxes ticked
PURPOSE-T decision pathway
Colour of boxes ticked N (%)
Total N (%)
At least one pink
box ticked
No pink boxes
and at least one
orange box ticked
Only blue and
yellow boxes
ticked
Expert nurse baseline
PU Category 1 or above or scarring 72 (31.3) 0 (0.0) 0 (0.0) 72 (31.3)
No PU, but at risk 0 (0.0) 109 (47.4) 2 (0.9) 111 (48.3)
No PU, not currently at risk 0 (0.0) 4 (1.7) 43 (18.7) 47 (20.4)
Total 72 (31.3) 113 (49.1) 45 (19.6) 230 (100.0)
Ward/Community nurse
PU Category 1 or above or scarring 63 (27.4) 0 (0.0) 0 (0.0) 63 (27.4)
No PU, but at risk 5 (2.2) 107 (46.5) 2 (0.9) 114 (49.6)
No PU, not currently at risk 0 (0.0) 5 (2.2) 47 (20.4) 52 (22.6)
Missing 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.4)
Total 68 (29.6) 113 (49.1) 49 (21.3) 230 (100.0)
Expert nurse follow-up
PU Category 1 or above or scarring 68 (31.3) 0 (0.0) 0 (0.0) 68 (31.3)
No PU, but at risk 2 (0.9) 104 (47.9) 1 (0.5) 107 (49.3)
No PU, not currently at risk 0 (0.0) 0 (0.0) 42 (19.4) 42 (19.4)
Total 70 (32.3) 104 (47.9) 43 (19.8) 217 (100.0)
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• Mobility when the patient is unable to communicate and after
only a short assessment period
• Sensory perception
• Medical history in community setting
• Poor nutritional intake
• BMI in community setting
5 | DISCUSSION
The PURPOSE-T clinical evaluation involved 230 patients, assessed
by both expert and ward/community nurses. Overall the level of
data completion for each construct on PURPOSE-T was high at
>90%, except for previous PU history. The inter-rater and test–retest
reliability as determined by the kappa statistic was “very good” for
the assessment decision overall. The observed percentage agreement
for the assessment of “problem/no problem” for the eight risk fac-
tors (mobility, skin, previous PU, sensory perception, perfusion, nutri-
tion, moisture and diabetes) was high for both inter-rater reliability
and test–retest reliability. The lowest levels of absolute agreement
were for the analysis of independent movement, a matrix item. This
is likely related to the increased number of assessment options avail-
able (i.e. does not move/does not move, moves occasionally/slight
position changes, move occasionally/major position changes, move
frequently/slight position changes and moves frequently/major posi-
tion changes) when compared with the other items. Indeed when
agreement was considered on presence/absence of a problem,
agreement was in line with other assessment items. As predicted
moderate to high associations were demonstrated for convergent
validity, assessed by comparison with the same or similar constructs
on other PU-RAIs (Braden and Waterlow) (Nixon et al., 2015).
An important feature of PURPOSE-T is the inclusion of skin
status which was identified, as a key predictor of PU development
(Coleman et al., 2013). This allows us to identify those who are at
risk of PU development and require primary prevention and those
who have an existing PU and require secondary prevention. Tradi-
tional RAIs were designed to identify “at risk” patients, that is
before they develop a PU, yet in practice they are used on all
patients (those with and without PUs) and do not distinguish
between these two groups (Coleman, 2014). Without skin assess-
ment nurses may not identify the presence of an existing PU and
fail to initiate escalated interventions, leading to the progression
of a severe PU (Pinkney et al., 2014). The results indicate that for
Waterlow and PURPOSE-T which incorporate skin status, all
patients with an existing PU were identified as “at risk” (for PUR-
POSE-T the red “Secondary prevention/treatment pathway” was
TABLE 4 Cross tabulation of expert nurse PURPOSE-T decision pathway at baseline by ward/community nurse decision pathway and
expert nurse decision pathway at follow-up
Inter-rater
Expert nurse baseline
Ward/community nurse
PU Category 1 or
above or scarring No PU but at risk
Not PU, not
currently at risk Total
PU Category 1 or above or scarring 54 (23.6) 18 (7.9) 0 (0.0) 72 (31.4)
No PU, but at risk 9 (3.9) 91 (39.7) 10 (4.4) 110 (48.0)
No PU, not currently at risk 0 (0.0) 5 (2.2) 42 (18.3) 47 (20.5)
Total 63 (27.5) 114 (49.8) 52 (22.7) 229 (100.0)
At risk Not at risk Total
At risk 172 (75.1) 10 (4.4) 182 (79.5)
Not at risk 5 (2.2) 42 (18.3) 47 (20.5)
Total 177 (77.3) 52 (22.7) 229 (100.0)
Test–retest
Expert nurse baseline
Expert nurse follow-up
PU Category 1 or
above or scarring No PU but at risk
Not PU, not
currently at risk Total
PU Category 1 or above or scarring 64 (30.0) 5 (2.3) 0 (0.0) 69 (32.4)
No PU, but at risk 3 (1.4) 95 (44.6) 5 (2.3) 103 (48.4)
No PU, not currently at risk 0 (0.0) 4 (1.9) 37 (17.4) 41 (19.2)
Total 67 (31.5) 104 (48.8) 42 (19.7) 213 (100.0)
At risk Not at risk Total
At risk 167 (78.4) 5 (2.3) 172 (80.8)
Not at risk 4 (1.9) 37 (17.4) 41 (19.2)
Total 171 (80.3) 42 (19.7) 213 (100.0)
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allocated), whereas 17.2% of those assessed as “not at risk” by
Braden, which does not include skin status actually had an exist-
ing PU. It maybe that these patients were recovering and not
considered “at risk” of new PU development but they should still
be considered a priority in clinical practice. It was beyond the
scope of this study to assess whether their “not at risk” status
had an impact on the intensity of the interventions received.
The field notes recorded by the expert nurses highlighted positive
and problem aspects of using PURPOSE-T in the clinical environment
(Nixon et al., 2015). Negative aspects included difficulties in assessing
some of PURPOSE-T items and concerns about reliability, but these
were not evidenced in the formal evaluation of inter-rater and test–
retest reliability. It is of note that where only yellow and blue data
items were present both expert and ward/community nurses allo-
cated the majority of patients (>95%) to the “not at risk” category,
with clinical decision-making reflecting systematic review evidence
(Coleman et al., 2013) that there is a weaker relationship between
these factors and PU development (Nixon et al., 2015).
The issues raised in the field notes and emerging evidence
from the PURPOSE pain cohort study (Nixon et al., 2015) indicat-
ing pain as a predictor of PU development were considered in a
post-clinical evaluation review of PURPOSE-T by the expert group
and PU Research Service User Network (PURSUN UK http://
www.pursun.org.uk/) involved in the earlier consensus study
(Coleman, Nelson et al., 2014). The review resulted in final
amendments to PURPOSE-T and the inclusion of pain in the stage
2 skin assessment section. PURPOSE-T and supporting literature
is freely available for academic research and clinical use and can
be downloaded following web-based registration http://medhealth.
leeds.ac.uk/accesspurposet). It has since been implemented in
TABLE 6 Cross tabulation of PURPOSE-T with the Waterlow and the Braden scales—overall risk
PURPOSE-T overall risk status
Waterlow overall risk status N (%)
Correlation coefficientAt risk (≥10) Not at risk (<10) Total
At risk 175 (76.1) 8 (3.5) 183 (79.6) Phi 0.63—Moderate
Not at risk 18 (7.8) 29 (12.6) 47 (20.4)
Total 193 (83.9) 37 (16.1) 230 (100.0)
Braden overall risk status N (%)
PURPOSE-T overall risk status At risk (≤18) Not at risk (>18) Total Correlation coefficient
At risk 50 (29.6) 73 (43.2) 123 (72.8) Phi 0.40—Moderate
Not at risk 0 (0.0) 46 (27.2) 46 (27.2)
Total 50 (29.6) 119 (70.4) 169 (100.0)
TABLE 5 Levels of agreement between expert nurses and ward/community nurses and between expert nurses at baseline and at follow-up
for specific risk factor items
Item
Expert nurse vs.
ward nurse
Expert nurse baseline
vs. follow-up
Step 1: Mobility (absolute agreement) 156/228 (68.4%) 165/212 (77.8%)
Step 1: Mobility (agreement on presence/absence of problem) 207/228 (90.8%) 197/212 (92.9%)
Skin status [step 1 and 2 combined] (absolute agreement) 189/230 (82.2%) 191/213 (89.7%)
Skin status [step 1 and 2 combined] (agreement on presence/absence of problem) 204/230 (88.7%) 200/213 (93.9%)
Analysis of independent movement (absolute agreement) 113/191 (59.2%) 114/177 (64.4%)
Analysis of independent movement (agreement on presence/absence of problem) 165/191 (86.4%) 147/177 (83.1%)
PU History 160/191 (83.7%) 165/177 (93.2%)
Sensory perception 151/191 (79.1%) 154/177 (87.0%)
Nutrition (problem vs. no problem) 156/191 (81.7%) 154/177 (87.0%)
Unplanned weight loss 159/191 (83.2%) 159/177 (89.8%)
Poor nutritional intake 163/191 (85.3%) 159/177 (89.8%)
Low BMI 176/191 (92.1%) 170/177 (96.0%)
High BMI 170/191 (89.0%) 165/177 (93.2%)
Diabetic status 180/191 (94.2%) 166/177 (93.8%)
Perfusion status (absolute agreement) 125/191 (65.4%) 138/177 (78.0%)
Perfusion status (agreement on presence/absence of problem) 139/191 (72.8%) 154/177 (87.0%)
Moisture status (absolute agreement) 145/191 (75.9%) 155/177 (87.6%)
Moisture status (agreement on presence/absence of problem) 155/191 (81.2%) 159/177 (89.8%)
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TABLE 7 Cross tabulations of dichotomized PURPOSE-T constructs with relevant constructs on the Waterlow and the Braden scales
PURPOSE T mobility Step
1
Braden Mobility
Correlation
coefficientNo limitation
Slightly/very limited/
completely immobile Total
No problem 69 (30.1%) 10 (4.4%) 79 (34.5%) Phi 0.60—Moderate
Problem 37 (16.2%) 113 (49.3%) 150 (65.5%)
Total 106 (46.3%) 123 (53.7%) 229 (100.0%)
PURPOSE T mobility Step 1
Braden Activity
Correlation
coefficientWalks frequently
Walks occasionally,
chairfast or bedfast Total
No problem 56 (24.5%) 23 (10.0%) 79 (34.5%) Phi 0.66—Moderate
Problem 11 (4.8%) 139 (60.7%) 150 (65.5%)
Total 67 (29.3%) 162 (70.7%) 229 (100.0%)
PURPOSE T Sensory
response and Perception
Braden Sensory
Correlation
coefficientNo impairment
Slightly, very or
completely limited Total
No problem 134 (70.9%) 7 (3.7%) 141 (74.6%) Phi 0.74—High
Patient unable to feel
and/or
respond appropriately to
discomfort from
pressure
11 (5.8%) 37 (19.6%) 48 (25.4%)
Total 145 (76.7%) 44 (23.3%) 189 (100.0%)
PURPOSE T nutrition
Braden Nutrition
Correlation
coefficient
Excellent or
adequate
probably
inadequate
or very poor Total
No problem 93 (48.2%) 1 (0.5%) 94 (48.7%) Phi 0.58—Moderate
Problem 47 (24.4%) 52 (26.9%) 99 (51.3%)
Total 140 (72.5%) 53 (27.5%) 193 (100.0%)
PURPOSE T nutrition
Waterlow malnutrition screening tool:
Patient
eating poorly or lack of appetite
Correlation
coefficientYes No Total
Problem 64 (33.7%) 35 (18.4%) 99 (52.1%) Phi 0.60—Moderate
No problem 6 (3.2%) 85 (44.7%) 91 (47.9%)
Total 70 (36.8%) 120 (63.2%) 190 (100.0%)
PURPOSE T nutrition—poor
nutritional intake
Braden Nutrition
Correlation coefficient
Probably inadequate or
very poor Excellent or adequate Total
Yes 50 (25.9%) 12 (6.2%) 62 (32.1%) Phi 0.82—High
No 3 (1.6%) 128 (66.3%) 131 (67.9%)
Total 53 (27.5%) 140 (72.5%) 193 (100.0%)
PURPOSE T
nutrition—poor
nutritional intake
Waterlow malnutrition screening tool:
Patient eating poorly or lack of appetite
Correlation coefficientYes No Total
Yes 57 (30.0%) 5 (2.6%) 62 (32.6%) Phi 0.79—High
No 13 (6.8%) 115 (60.5%) 128 (67.4%)
Total 70 (36.8%) 120 (63.2%) 190 (100.0%)
(Continues)
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TABLE 8 Cross-tabulations of dichotomized PURPOSE-T constructs with relevant constructs on the Waterlow and the Braden scales
PURPOSE T Step 2 Analysis
of independent movement
Braden mobility
Correlation
coefficient
Completely
immobile
Very or slightly
limited No limitation Total
Does not Move 7 (3.6%) 4 (2.1%) 0 (0.0%) 11 (5.7%) Spearman rank
0.62—ModerateMoves occasionally and slight
or major position changes
or moves frequently with
slight position changes
1 (0.5%) 96 (49.7%) 26 (13.5%) 123 (63.7%)
Moves frequently and major
position changes
0 (0.0%) 12 (6.2%) 47 (24.4%) 59 (30.6%)
Total 8 (4.1%) 112 (58.0%) 73 (37.8%) 193 (100.0%)
PURPOSE T Step 2 Analysis
of independent movement
Braden Activity
Correlation
coefficientBedfast
Chairfast or walks
occasionally Walks frequently Total
Does not Move 6 (3.1%) 5 (2.6%) 0 (0.0%) 11 (5.7%) Spearman rank
0.55—ModerateMoves occasionally and slight
or major position changes or
moves frequently with slight
position changes
15 (7.8%) 102 (52.8%) 6 (3.1%) 123 (63.7%)
Moves frequently and major
position changes
0 (0.0%) 31 (16.1%) 28 (14.5%) 59 (30.6%)
Total 21 (10.9%) 138 (71.5%) 34 (17.6%) 193 (100.0%)
PURPOSE T skin status
Waterlow skin status
Correlation
coefficientHealthy
Tissue paper dry
oedematous clammy
Discoloured grade 1 or
broken spots grade 2–4 Total
Normal Skin 47 (20.6%) 18 (7.9%) 0 (0.0%) 65 (28.5%) Spearman rank
0.83—HighVulnerable skin 11 (4.8%) 79 (34.6%) 13 (5.7%) 103 (45.2%)
PU Category 1 (0.4%) 0 (0.0%) 59 (25.9%) 60 (26.3%)
Total 59 (25.9%) 97 (42.5%) 72 (31.6%) 228 (100.0%)
PURPOSE T Moisture
Braden Moisture
Correlation
coefficientRarely or occasionally moist Very moist Constantly moist Total
No problem/Occasional 154 (79.4%) 2 (1.0%) 0 (0.0%) 156 (80.4%) Spearman Rank
0.67—ModerateFrequent (2–4 times a day) 18 (9.3%) 12 (6.2%) 0 (0.0%) 30 (15.5%)
Constant 0 (0.0%) 4 (2.1%) 4 (2.1%) 8 (4.1%)
Total 172 (88.7%) 18 (9.3%) 4 (2.1%) 194 (100.0%)
PURPOSE T
nutrition—low BMI
Waterlow build or weight for height
Correlation coefficientBMI < 20 BMI ≥ 20 Total
Yes 21 (11.0%) 0 (0.0%) 21 (11.0%) Phi 0.72—High
No 16 (8.4%) 154 (80.6%) 170 (89.0%)
Total 37 (19.4%) 154 (80.6%) 191 (100.0%)
PURPOSE T nutrition—High BMI
Waterlow build or weight for height
Correlation coefficientBMI ≥ 30 BMI < 30 Total
Yes 22 (11.5%) 4 (2.1%) 26 (13.6%) Phi 0.74—High
No 9 (4.7%) 156 (81.7%) 165 (86.4%)
Total 31 (16.2%) 160 (83.8%) 191 (100.0%)
TABLE 7 (Continued)
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community and acute NHS Trusts and early indications are posi-
tive, though further evaluation of its impact in practice is needed.
Clinical evaluation allowed construct validity (convergent and dis-
criminant), inter-rater and test–retest reliability and clinical utility to
be evaluated. These are important building blocks in the development
of RAIs, yet have often been overlooked in the development of previ-
ous RAIs (Coleman, 2014) with only a few reporting the evaluation of
reliability during instrument validation (Bergstrom et al., 1987; Lind-
gren, Unosson, Krantz, & Ek, 2002; Suriadi et al., 2006) and a focus
on establishing predictive validity (Coleman, 2014). While this is an
important property, its evaluation is hampered by several important
factors, including the subjective nature of PU risk factor measure-
ment; the lack of a reference gold standard test (Kottner & Balzer,
2010)); the instigation of preventative interventions in routine prac-
tice having an impact on instrument performance (Deeks, 1996;
Defloor & Grypdonck, 2004; Gould et al., 2002) and; studies often
only assess the predictive validity of one instrument, rather than mul-
tiple RAIs in the same study population to allow comparison (Ferrante
di Ruffano, Hyde, Mccaffery, Bossuyt, & Deeks, 2012).
A major limitation of this traditional approach to PU-RAI validation
and evaluation, has been a failure to consider them as complex interven-
tions where their delivery contains several interacting components
(MRC, 2008) including the assessment itself, the potential outcomes and
decisions about care interventions set in the context of complex health-
care environments. Recent complex intervention guidance advocates
the use of process evaluations allowing causal mechanisms, contextual
factors and the quality of implementation to be considered alongside
clinical outcomes (Moore et al., 2015; MRC, 2008; Richards & Hallberg,
2015). Therefore in addition to predictive validity testing (alongside
other RAIs), the ongoing evaluation of PURPOSE-T will involve a realist
process evaluation to identify and test theories and underlying assump-
tions regarding its use in practice to learn how it can be best used in dif-
ferent contexts, to enhance the probability of effectiveness. This will
allow us to establish whether there is sufficient confidence that PUR-
POSE-T can “reasonably be expected to have a worthwhile effect”
(MRC, 2008) over a standard RAI and inform a potential future RCT.
5.1 | Limitations
The sample included in this study were overwhelmingly Caucasian.
The results, demonstrating the performance of PURPOSE-T should
not be applied to other groups without consideration of the impor-
tance of skin assessment as a core (and novel) element of this instru-
ment and the potential differences in skin assessment for people
with non-white skin.
The level of “training” in PURPOSE-T use, with expert nurses
trained by the researcher which was then cascaded to local nurses was
designed to replicate the roll-out of tools to NHS nurses. However,
the focussed training of the experts and their direct access to PUR-
POSE-T development team may mean that the achieved level of com-
petence might not necessarily be replicated in routine clinical practice.
6 | CONCLUSION
PURPOSE-T evaluation facilitated the initial validation and clinical
usability of the instrument. The results indicate very good inter-rater
TABLE 9 Summary of expert nurse field notes
Characteristic Positive aspects of using PURPOSE Problem aspects of using PURPOSE T
Layout • Easy to use and self-explanatory
• Quick to use
• Easier to use with familiarity
• All on one page
• Tool looked “busy” or “complicated”
• Font size small
• Space for skin assessment too small
Format • The RAG rating approach for assessment
decision and use of colour made distinctive
• Like the fact it did not use a score like
other risk assessment scales
• Form does not flow
• Unclear whether to progress to Step 2
• Concern that exiting at Step 1 would miss assessment of
important risk factors
• Nurses wanted to complete full skin assessment at step 1
Content • Thorough and included important risk factors
• Positive about the detailed skin assessment
and suggested that this encouraged more careful
skin assessment
• Inclusion of pressure ulcer scar as a risk factor
• Reliability of assessment of skin vulnerability
• Reliability of assessment of scarring
• Difficulty establishing history of previous pressure ulcer:
 Difficult and time consuming
 Where information available was of poor quality
(e.g. severity not clear)
• Duration of weight loss not specified
• Assessment of circulation items in patients with respiratory problems
• Analysis of movement difficult to categorize
Usability • Will be easy for nurses to remember and
report red boxes at handover
• Step 1 screening is efficient in allowing the
quick identification of those who do not require
a full assessment
• Not having to visually inspect pressure areas
when a patient was not at risk was appreciated
• Local production difficult if no colour printers available
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and retest reliability, high levels of data completion and moderate to
high associations for convergent validity, when the same or similar
constructs of PURPOSE-T were compared with other PU-RAIs.
The expert nurse field notes allowed the positive and negative
aspects of using the instrument to be captured. These along with
the other results were reviewed and some finals amendments were
made to PURPOSE-T. This culminated in the development of a new
evidenced-based RAI for use in adult populations and is now being
used in clinical practice. Further evaluation of its impact on care pro-
cesses and patient outcomes is planned.
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